Addition Therapeutics emerged from stealth today, announcing $100 million in financing to date to advance its mission to fulfill the promise of genomic medicine for people impacted by both chronic and rare diseases.
A spin-out of Professor Kathleen Collins’ laboratory at University of California, Berkeley, Addition leverages an all-RNA, non-viral, lipid nanoparticle (LNP)-based platform — known as PRINT (Precise RNA-Mediated Insertion of Transgenes) — to develop safer, durable, one-time therapies, overcoming limitations of current genetic medicine modalities.
The company is advancing a pipeline of PRINTed therapeutics that have the potential to redefine how chronic and rare diseases are treated. Initial disease-related non-human primate studies are planned for 2026.
Investors include SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation and BEVC.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!